Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder

Authors:

Abstract
Opioid-involved overdose deaths remain at high levels in the US, driven primarily by synthetic opioids such as illegally made fentanyl (IMF).1,2 In 2021, 80 816 opioid-involved overdose deaths occurred,1 and an estimated 5.6 million persons aged 12 years and older had an opioid use disorder (OUD) in the US, based on the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria for heroin or prescription pain reliever use disorder in the National Survey on Drug Use and Health (NSDUH).3 Medications for OUD (MOUD)—buprenorphine, naltrexone, and methadone—approved for OUD treatment by the Food and Drug Administration are highly effective treatments to support recovery from OUD and reduce risk of opioid overdose.4-7 Expanding access to MOUD treatment is a cornerstone of the response to the opioid overdose crisis.8,9

This publication has 29 references indexed in Scilit: